Skip to main content
ViGenCell Inc. logo

ViGenCell Inc. — Investor Relations & Filings

Ticker · 308080 ISIN · KR7308080001 KO Professional, scientific and technical activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2024-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 308080

About ViGenCell Inc.

https://www.vigencell.com/en/

ViGenCell Inc. is a biotechnology company specializing in the development of immune cell therapies. The company focuses on creating treatments for cancer and other incurable diseases by enhancing a patient's own immunity. Its core technologies include the ViTier platform, which utilizes antigen-specific killer T cells to target and remove cancer cells, and the ViRanger platform, a T-cell gene therapy technology. These proprietary platforms form the basis of its pipeline of novel immune cell therapeutics designed to prolong life and improve patient outcomes.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Vigencell Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management reference materials (business overview, industry outlook, and pipeline information) required by Korean commercial law for shareholders prior to the AGM. This document is the official proxy statement/information package provided to shareholders to solicit votes for the upcoming meeting.
2024-03-11 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Vigencell Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management reference materials (경영참고사항) such as director activity reports and business outlooks. This document is a standard proxy statement/notice of meeting sent to shareholders to inform them of the upcoming AGM and solicit their votes, which fits the 'Proxy Solicitation & Information Statement' category.
2024-03-11 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company '바이젠셀'. It outlines the date, location, and agenda items (such as financial statement approval and director remuneration). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2024-02-22 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). This document details the shareholding status, changes in ownership (acquisitions/disposals), and the relationship between the reporting entity and the issuer. It is a standard regulatory disclosure form, not an annual report, earnings release, or announcement of a report. Therefore, it falls under the 'Major Shareholding Notification' category.
2024-01-16 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It does not contain the full meeting materials or the results of the meeting, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure regarding meeting preparation, it falls under the general regulatory filing category.
2023-12-14 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees/executives, including the number of shares, exercise price, and legal basis. In the context of corporate filings, the issuance of stock options or changes in capital structure that do not fit into specific categories like 'Share Issue' (SHA) or 'Director's Dealing' (DIRS) are typically classified as general regulatory filings (RNS) in this taxonomy, as they represent a mandatory disclosure to the financial authorities (Financial Services Commission/Korea Exchange).
2023-12-13 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.